BioSim™ anti-Bevacizumab (Human) ELISA Kit

(No reviews yet) Write a Review
SKU:
26-E4389
Availability:
Usually Shipped in 5 Working Days
Size:
100 Assays
Storage Conditions:
4°C
Shipping Conditions:
Gel Pack
Shelf life:
12 months
zł6,654.74
Frequently bought together:

Description

Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. It has been demonstrated that bevacizumab, in combination with chemotherapy, resulted in increased survival in patients with previously untreated metastatic colorectal cancer relative to chemotherapy alone, leading to FDA approval of the first anti-angiogenic agent. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Bevacizumab ELISA kit is designed to quantify/measure the antibody against Bevacizumab with high specificity and sensitivity in biological matrices.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the quantitative measurement of antibody against Bevacizumab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of antibody against Bevacizumab in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of antibody against Bevacizumab in human serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method to measure the level of antibody against Bevacizumab in human serum and plasma. Detection Range: 62 - 500 ng/ml Sensitivity: 30 ng/ml Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) Cross Reactivity: Bevacizumab infusion camouflages/masks the presence of antibody to Bevacizumab (ATA) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATA. It is convenient to obtain blood sample just before the infusion of Bevacizumab or at least 2 weeks after the infusion of Bevacizumab. Recovery rate: 85 – 115% with normal human serum samples with known concentrations

View AllClose